
Discussing Rheumatology: Herpes Zoster and HBV
Prof Iain McInnes discusses the risk of herpes zoster in RA patients taking biologics and DMARDS. He also discusses reactivation of hepatitis B in patients with RA taking tofacitinib. Keep-up to date...
4 Nov 20217min

ACR 2021: Day 1 Highlights
Prof Calabrese presents the Day 1 highlights of the key abstracts and posters presented at ACR 2021.
4 Nov 202110min

ACR 2021 Preview Podcast
A preview of the latest research at ACR 2021. Prof Ritchlin highlights important abstracts in cytokine signalling at the upcoming ACR Convergence.
4 Nov 202113min

Rheumatology Author Professor Paul Bird: Tofacitinib Effectiveness
Paul Bird, Conjoint Professor at the University of South Wales. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Paul Bird assess the re...
14 Okt 202119min

Discussing Rheumatology: Poor Prognostic Factors, Monotherapy, and Combination Therapy
Prof Iain McInnes discusses poor prognostics factors from the FINCH 3 study, and the effectiveness and persistence of monotherapy and combination therapy from the Australian OPAL study. Keep-up to da...
23 Sep 20218min

Rheumatology Author Professor Kurt de Vlam: Pain Improvements
Kurt de Vlam, Professor of Rheumatology at UZ Leuven, Belgium. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor de Vlam assess th...
10 Sep 202128min

Rheumatology Author Professor Strand: Upadacitinib and PROs
Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology/Rheumatology, Biopharmaceutical Consultant at Stanford University School of Medicine. Join Professor Peter Nash as he interview...
9 Sep 202125min

Discussing Rheumatology: Patient Reported Outcomes
Prof Iain McInnes discusses an essential part of the assessment of patients with rheumatic diseases; patient reported outcomes, or PROs. Improving PROs is crucial to effect tangible change in diseases...
9 Sep 202112min



















